PARP inhibitors exploit the fundamental weakness of ovarian cancers with HR repair defects and show promising antitumor effects in ovarian cancers with BRCA1/2 mutations.14, 15, 16, 17. This evidence concerns the gene PARP1 and ovarian cancer.